My Mental Health Journey enrollees are currently enrolling adults living in the United States who are experiencing symptoms of depression.
The Otsuka Pharmaceutical-sponsored registry study is supported by Verily and aims to advance depression and mental health research and help develop more precise treatment options.
Princeton, NJ and South San Francisco, CA, April 4, 2024–(BUSINESS WIRE)–Otsuka Pharmaceutical Development and Commercial Co., Ltd. (Otsuka Pharmaceutical), a global pharmaceutical company, my mental health journey, a longitudinal registry study aimed at advancing depression and mental health research. Verily Life Sciences LLC (Verily), a precision medical technology company, will recruit participants and conduct the study.
of my mental health journey The registry will enroll U.S.-based adults who experience symptoms of depression, allowing Otsuka to better understand mental health conditions such as major depressive disorder across time and in real-world settings. We plan to support you in this way. Adults aged 18 and older will participate in this observational study by securely sharing their own depression history through regular self-assessments and digital data collection. In addition to contributing to mental health and depression research, participants will have access to the latest information on depression and other mental health-related topics, and will be better prepared to participate in future clinical research studies. You will find a reasonable path.
“Depression is a leading cause of disability worldwide, with more than one in six U.S. adults reporting being depressed or receiving treatment for depression,” Otsuka said. said John Kraus, MD, Pharmaceutical’s executive vice president and chief medical officer. “Our work with Verily will enable us to better understand how patients with depression are cared for and ultimately provide specific treatments that can support patients in the early stages of their mental health journey. .”
my mental health journey is powered by Verily Viewpoint, an end-to-end solution suite that powers evidence generation. This includes Verily’s recruitment services, longitudinal registry, and multimodal data platform. The registry is designed with the participant experience first, leveraging best-in-class user experience, technology, and clinical expertise to understand the patient journey and engage diverse populations. Insights generated from the registry will be used by Otsuka to drive future research, informing areas such as trial design, site selection, and health outcomes research.
“We are excited to help usher in the era of precision in mental health care by leveraging multimodal data to more fully understand an individual’s treatment journey,” said Verily’s Chief Medical Science Officer. , says Andrew Trister, MD. . “Our work with Otsuka promises to accelerate the development and delivery of innovative depression treatments and serve millions of patients in need of safe, effective and accessible care. To do.”
Otsuka Pharmaceutical has been working with Verily since 2019 to apply new clinical trial solutions across its product portfolio. As Otsuka and Verily expand the registry, Otsuka and Verily plan to integrate additional data sources with participant consent, initiate additional cohorts and substudies, and develop new digital biomarkers to advance research. .
Recruiting eligible participants
Would you like to participate in a virtual depression study? my mental health journey We are currently recruiting participants in the United States. If you or a loved one know someone who is struggling with symptoms of depression and are interested in getting involved, click here. [here] Check eligibility and get more information about the program.participants of my mental health journey We may receive compensation for research activities, educational resources, updates on future clinical research, and other opportunities to support the advancement of depression research.
About Verily
Verily Life Sciences LLC is an Alphabet health technology company focused on research, care and health finance to deliver on the promise of precision health and empower people to live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, products that enable more personalized care, and approaches that make costs more predictable. For more information, please visit verily.com.
About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company whose corporate philosophy is “Otsuka creates new products for the health of people around the world.” Otsuka Pharmaceutical researches, develops, manufactures, and sells innovative products, focusing on pharmaceuticals that meet unmet medical needs and nutritional supplements for maintaining daily health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health, as well as in oncology and several poorly addressed areas, including tuberculosis, a major global public health problem. We are conducting additional research programs on diseases that are not available. These efforts demonstrate that Otsuka is essentially a “big venture” company, applying a spirit of young creativity to all its activities.
Otsuka Pharmaceutical established its presence in the United States in 1973, and its U.S. affiliates currently include Otsuka Pharmaceutical Development & Commercialization Co., Ltd. (OPDC) and Otsuka America Pharmaceutical Co., Ltd. (OAPI). His 2,000 U.S. employees at these two companies develop and commercialize medicines in the areas of mental health and kidney disease, using cutting-edge technology to address unmet medical needs. Masu.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo. The Otsuka Group has 34,400 employees worldwide and had consolidated sales of approximately $14.2 billion in 2023.
Otsuka’s stories all begin by walking down the road less traveled. For more information about Otsuka Pharmaceutical USA, please visit www.okka-us.com. Also, connect with us on LinkedIn and Twitter. @Otsuka US. Otsuka Pharmaceutical Co., Ltd.’s global website can be accessed from https://www.okka.co.jp/ja/.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240404726198/ja/
contact address
stephen cooper
Head of Media Relations, Verily
sjcoop@verily.com
Jill Roman
Senior Manager, Media Relations
Corporate communications and marketing
Otsuka America Pharmaceutical Co., Ltd.
jill.roman@okka-us.com
